The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Orally bioavailable, synthetic nonpeptide agonists (NPAs) of the glucagon-like peptide-1 receptor (GLP-1R) may offer an effective, scalable pharmacotherapy to address the metabolic disease epidemic. One of the first molecules in the emerging class of GLP-1R NPAs is orforglipron, which is in clinical development for treating type 2 diabetes and obesity. Here, we characterized the pharmacological properties of orforglipron in comparison with peptide-based GLP-1R agonists and other NPAs. Competition binding experiments using either [ 125 I]GLP-1(7-36)NH 2 or [ 3 H]orforglipron indicated that orforglipron is a high-affinity [inhibition constant ( K i ) = 1 nM], selective ligand of the human GLP-1R. Signal transduction assays showed that orforglipron has low intrinsic efficacy for effector activation and negligible β-arrestin recruitment. To evaluate GLP-1R engagement in vivo, mice expressing the human GLP-1R were administered orforglipron and subjected to a glucose tolerance test. Predicted receptor occupancy was calculated using the receptor K i value of orforglipron and its unbound concentration in vivo that reduces hyperglycemia. These experiments revealed that low GLP-1R occupancy by orforglipron is sufficient to yield a full biological response. Moreover, in a model where CRISPR-Cas9 gene editing was used to sensitize the rat GLP-1R ( Glp1r S33W ) to GLP-1R NPAs, target engagement by orforglipron in the pancreas and brain was consistent with peptide-based GLP-1R agonists. Diet-induced obesity in Glp1r S33W rats enabled studies showing weight loss in animals orally administered orforglipron versus subcutaneous injection of GLP-1R agonist semaglutide. Furthermore, crossover studies indicated oral orforglipron can sustain efficacy initiated by parenteral semaglutide. The pharmacological properties of orforglipron may inform targeting of other peptide receptors with NPAs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Small-molecule, orally bioavailable, synthetic nonpeptide GLP-1 receptor agonists can provide an effective pharmacotherapy as an alternative to peptide-based GLP-1 receptor agonists, without a need for injection.120,121”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [120]
In the citing paper
“Mechanistically, orforglipron differs fundamentally from peptide GLP-1 RAs in its mode of receptor engagement. Whereas endogenous GLP-1 and peptide agonists bind primarily to the orthosteric binding pocket of the GLP-1 receptor, orforglipron acts as a nonpeptide allosteric agonist [40].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [40]
In the citing paper
“Structural and modeling data indicate that it occupies a pocket formed primarily by TM1, TM2, TM3, TM7, and ECL2, engaging key hydrophobic residues in TM3 and TM7 and stabilizing an active receptor conformation.”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [40]
In the citing paper
“Importantly, biased signaling analyses indicate that orforglipron preferentially activates pathways associated with metabolic efficacy rather than receptor internalization, which may contribute to sustained pharmacodynamic effects despite once-daily dosing.”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [40]
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., et al. (2017) · Nature · doi:10.1038/nature22394 · Cited by 576
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
Self-citation
Research works printed but not linked: 1
- T. P. Kenakin A Pharmacology Primer: Techniques for More Effective and Strategic Drug (Academic Press ed. 6 2022).
Cited by
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“…the GLP-1R (edited to confer human GLP-1R responsivity) both in islets and CNS neurons, producing pharmacodynamic actions (c-Fos induction, reduction of food intake, body weight and glycaemia) to a similar extent relative to that achieved with peptide GLP-1RAs such as exenatide or semaglutide 53 .”
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 25
“57,58 This may explain its pronounced glucose-lowering and weight-reduction effects.”
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“This binding site partially overlaps with the orthosteric peptide pocket but extends into a distinct transmembrane sub-pocket, a feature thought to underlie the G s -biased signaling profile of orforglipron compared with other GLP-1R agonists [40].”
Metadata
- Authors
- Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., O’Farrell, L. S., Hewitt, N., Ruble, J. C., Padgett, L. R., Woerly, E. M., Peterson, J. A., Coskun, T., Liu, Z., Coutant, D. E., Ai, M., Emmerson, P. J., Sangwung, P., & Willard, F. S.
- Affiliations
- Eli Lilly (United States) (US)
- Diabetes, Obesity and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
- Corresponding author
- Sloop, Kyle W.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2024-12-18
- Volume
- 16
- Issue
- 778
- Pages
- eadp5765-eadp5765
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4405516956
- Cited by
- 52
- References
- 43
- Citations by year
- 2026: 36 · 2025: 15 · 2024: 1
- FWCI
- 17.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- orforglipron, GLP-1 receptor, type 2 diabetes, obesity, receptor occupancy, target engagement, semaglutide, glucose tolerance, beta-arrestin, intrinsic efficacy, oral bioavailability, crossover design, metabolic disorders
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Glucose Tolerance Test, Humans, Male, Mice, Inbred C57BL, Oxadiazoles, Signal Transduction, Fluorine Compounds, Mice, Rats, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. https://app.cochat.ai/papers/10.1126/scitranslmed.adp5765
- The paper
- Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., O’Farrell, L. S., Hewitt, N., Ruble, J. C., Padgett, L. R., Woerly, E. M., Peterson, J. A., Coskun, T., Liu, Z., Coutant, D. E., . . . Willard, F. S. (2024). The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adp5765
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.